Calamos Advisors’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
Other funds holding IRMD
CCM
VCM
NTCM
Calamos Advisors's IRMD Position: Q1 2026 in Review
Calamos Advisors reduced its iRadimed (IRMD) stake by 21% in Q1 2026, selling an estimated $224K and leaving 8,546 shares worth $823K. The position accounts for ﹤0.01% of the portfolio, ranked #817.
Calamos Advisors first reported a position in IRMD in Q3 2018 and has held it in 19 quarters since. The position peaked at $3.93M in Q1 2022. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Calamos Advisors held 8,546 shares of iRadimed worth $823K as of Q1 2026.
- Calamos Advisors sold 2,242 iRadimed shares in Q1 2026, an estimated $224K.
- iRadimed made up ﹤0.01% of Calamos Advisors's portfolio in Q1 2026, its #817 holding.
- Calamos Advisors first reported a position in iRadimed in Q3 2018 and has held it in 19 quarters since.
- Calamos Advisors's iRadimed position peaked at $3.93M in Q1 2022.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.